Internal radiation boost may help fight esophageal cancer when standard treatment fails
NCT ID NCT07152678
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding high-dose-rate brachytherapy (internal radiation) to the immune therapy drug nivolumab can improve outcomes for people with advanced esophageal cancer that has not been fully controlled by standard chemoradiation. About 60 participants will receive 1-2 sessions of brachytherapy along with continued nivolumab. The study will track how many patients remain cancer-free in the chest area after 12 months and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nivolumab (immune therapy drug) and high-dose-rate brachytherapy (internal radiation)
- What this could lead to
- If successful, this combination could reduce the chance of esophageal cancer returning in the chest area after standard treatment.
- What could go wrong
- This is a small, early-phase trial with only 60 participants, so results may not apply to everyone. Adding brachytherapy to immune therapy could increase side effects like inflammation or damage to the esophagus.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Taiwan University Hospital Yunlin Branch
RECRUITINGHuwei, Yunlin County, 632, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- A high-tech camera may take the guesswork out of spotting a dangerous surgery complication
- Blood test score may flag High-Risk esophageal surgery patients
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can surgery for stomach or esophageal cancer cloud the mind?